Shenzhen Neptunus Bioengineering Co Supply Chain
Supply Chain of Shenzhen Neptunus Bioengineering Co (000078.SZ) as of Oct 28, 2026.
Get this data via API
Financial Data API
Supply Chain
-
Last updated:
Supply chains in stock corporations are essential components of business infrastructure and play a crucial role in value creation and competitiveness. These supply chains encompass all steps from raw material procurement and production to the delivery of finished products to the end customer.
Shenzhen Neptunus Bioengineering Co Supply Chain
Correlation: how closely stock prices move together
Same directionNo relationOpposite
3 companies
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.30 | 0.27 | 0.87 | ||
| 2 | -0.29 | -0.49 | 0.51 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.48 | -0.54 | -0.01 |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Shenzhen Neptunus Bioengineering Co Stock analysis
What does Shenzhen Neptunus Bioengineering Co do? Shenzhen Neptunus Bioengineering Co., Ltd. generates revenue through its pharmaceutical products and healthcare offerings. The company produces anti-tumor products, cardiovascular drugs, marine drugs, respiratory drugs, anti-infective products, and other pharmaceuticals. It also sells healthcare products, health food, and medical instruments. The primary market for these products is the domestic market, with East China being the main regional focus. The company serves healthcare providers, hospitals, and consumers within China's pharmaceutical sector.
Neptunus targets the Chinese domestic market, emphasizing East China as its core region. Its product portfolio spans multiple therapeutic areas including oncology, cardiology, respiratory care, and infection control. The company's distribution network focuses on reaching hospitals and healthcare facilities across China, particularly in the East China region. The firm's health food and medical instrument lines complement its pharmaceutical business, creating diversified revenue streams within the healthcare industry.
The business model relies on selling established pharmaceutical products alongside healthcare and medical solutions. Anti-tumor products and cardiovascular drugs form key segments of its revenue, supported by marine drugs and respiratory medications. East China's dominance in sales reflects the company's strategic market focus. The company's full-time employee count of 9,874 supports its manufacturing and distribution operations across China's domestic market. Shenzhen Neptunus Bioengineering Co is one of the most popular companies on Eulerpool.
All Key Metrics — Shenzhen Neptunus Bioengineering Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth